Martina M.d. Flammer - 28 May 2024 Form 4 Insider Report for INSMED Inc (INSM)

Role
Chief Medical Officer
Signature
/s/ Martina Flammer, M.D., by Michael A. Smith as Attorney-in-fact
Issuer symbol
INSM
Transactions as of
28 May 2024
Net transactions value
-$3,357,148
Form type
4
Filing time
30 May 2024, 17:43:10 UTC
Previous filing
17 May 2024
Next filing
12 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INSM Common Stock Options Exercise $2,456,050 +103,806 +98% $23.66 209,940 28 May 2024 Direct F1
transaction INSM Common Stock Sale $5,150,854 -103,806 -49% $49.62 106,134 28 May 2024 Direct F1, F2
transaction INSM Common Stock Options Exercise $503,381 +21,195 +20% $23.75 127,329 30 May 2024 Direct F1
transaction INSM Common Stock Sale $1,165,725 -21,195 -17% $55.00 106,134 30 May 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INSM Stock Option (right to buy) Options Exercise $0 -103,806 -85% $0.000000 18,874 28 May 2024 Common Stock 103,806 $23.66 Direct F1, F3
transaction INSM Stock Option (right to buy) Options Exercise $0 -21,195 -38% $0.000000 35,325 30 May 2024 Common Stock 21,195 $23.75 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2 This is the weighted average sales price representing 103,806 shares sold at prices ranging from $49.53 to $50.00 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F3 The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable.